Drug recall management and channel coordination under stochastic product defect severity: a game-Theoretic analytical study

Abstract

This paper analytically explores drug recall programmes in the pharmaceutical industry by considering the product defect severity as a source of uncertainty. Under the Stackelberg game model, a pharma-manufacturer outsources the drug recall management and pays collecting fees to a third party logistics provider (3PL) for collecting the defective medications. On the other side, the 3PL provides incentives to customers to facilitate product recall. In this research, we first analytically show the negative effect of lack of coordination between the pharma-manufacturer and 3PL. Then, a new coordination model, namely collecting fee agreement is proposed under which the pharma-manufacturer aims to motivate the 3PL to collect more defective medications. This research also analytically explores the effect of orchestrating the collecting fees and incentives under stochastic product defect severity. Finally, a Nash-bargaining game model is proposed to share the profits between the pharma-manufacturer and 3PL under the collecting fee agreement. Both analytical and numerical results reveal that the collecting fee agreement not only increases the collection rate of defective items and protects the patients from unsafe products, but also simultaneously improves the performances of whole pharmaceutical supply chain and its members while reducing the governmental penalties imposed on the pharma-manufacturer.

Keywords:

• Pharmaceutical supply chain
• drug recall
• supply chain coordination
• game theory
• stochastic product defect severity

Acknowledgments

We are very grateful to the associate editor and the two anonymous reviewers for their helpful comments and suggestions, which helped us improve the current paper.

Disclosure statement

No potential conflict of interest was reported by the author(s).

ORCID

Seyyed-Mahdi Hosseini-Motlagh http://orcid.org/0000-0003-2568-187X

Nazanin Nami http://orcid.org/0000-0003-0880-3636

Notes

1 BoardVitals Company (2017).

2 For detailed discussion see Nagarajan and Sošić (2008).

3 We sincerely thank an anonymous reviewer, who motivated us to include this extended model in the paper and improve the quality of this paper.